Cite
HARVARD Citation
Oaknin, A. et al. (n.d.). Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC). European journal of cancer. pp. S95-. [Online].